CRS3123 for C. difficile
Keystone Symposia: Antimicrobial Resistance & Microbiome Presentation
Presentation Details Poster: Phase 2 Clinical Trial Design for CRS3123, a Novel Narrow-Spectrum...
Read More
Presentation: World Antimicrobial Resistance (WAMR) Conference 2022
Presentation Details Poster Presentation: Addressing the AMR Challenge: Antibiotics with a Novel...
Read More
C. diff Infection Symptoms: An Overview
Clostridium difficile infection (CDI) is a gastrointestinal condition caused by toxin-producing...
Read More
Presentation at the 2022 National C. Diff Advocacy Summit
Presentation Details Crestone presents at the largest gathering of C. diff advocates and allies in...
Read More
Presentation at the C. diff International Conference & Health EXPO
Presentation Details Crestone, Inc. presents at the C. diff. International Conference & Health...
Read More
Crestone, Inc. joins the Antimicrobials Working Group
Crestone, Inc. joins the Antimicrobials Working Group to Combat Drug Resistant Infections June 8,...
Read More
First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track Designations
Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to...
Read More
NIH Funding Secured for Preclinical Development of Novel Antibiotic CRS3123
Crestone, Inc. Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to...
Read More
NIH Funding Secured for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123
Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate,...
Read More
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Clinical Studies
Learn how you can become part of our ongoing clinical study to fight deadly GI tract infections.